Robert Lanza Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Robert Lanza.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Robert Lanza. Robert Lanza is Chief Scientific Officer in Ocata Therapeutics, Inc. ($ACTC).
Latest Insider Trading Transactions of Robert Lanza
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Nov 12 2013 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Option Exercise | A | 0.06 | 1,285,714 | 79,714 | 1,285,714 | |
| Nov 12 2013 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Grant | A | 0.00 | 1,285,714 | 0 | 23,943,822 | 25.2 M to 23.9 M (-5.10 %) |
| Dec 18 2012 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 0.06 | 43,000 | 2,580 | 26,476,227 | 26.5 M to 26.5 M (-0.16 %) |
| Dec 18 2012 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 0.06 | 100,000 | 5,940 | 26,519,227 | 26.6 M to 26.5 M (-0.38 %) |
| Dec 18 2012 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 0.06 | 150,000 | 8,895 | 26,619,227 | 26.8 M to 26.6 M (-0.56 %) |
| Dec 18 2012 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 0.06 | 545,490 | 32,184 | 26,769,227 | 27.3 M to 26.8 M (-2.00 %) |
| Dec 18 2012 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 0.06 | 40,000 | 2,340 | 27,314,717 | 27.4 M to 27.3 M (-0.15 %) |
| Dec 18 2012 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 0.06 | 440,000 | 25,520 | 27,354,717 | 27.8 M to 27.4 M (-1.58 %) |
| Dec 18 2012 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 0.06 | 20,000 | 1,158 | 27,794,717 | 27.8 M to 27.8 M (-0.07 %) |
| Dec 18 2012 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Grant | A | 0.00 | 1,285,714 | 0 | 27,814,717 | 26.5 M to 27.8 M (+4.85 %) |
| Aug 01 2012 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 0.08 | 500,000 | 40,000 | 26,529,003 | 27 M to 26.5 M (-1.85 %) |
| Aug 01 2012 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 0.08 | 190,000 | 15,580 | 27,029,003 | 27.2 M to 27 M (-0.70 %) |
| Aug 01 2012 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 0.08 | 546,793 | 44,290 | 27,219,003 | 27.8 M to 27.2 M (-1.97 %) |
| Aug 01 2012 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 0.08 | 151,500 | 12,135 | 27,765,796 | 27.9 M to 27.8 M (-0.54 %) |
| Aug 01 2012 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 0.08 | 611,707 | 48,937 | 27,917,296 | 28.5 M to 27.9 M (-2.14 %) |
Page: 1